A consultant physician and Director of Research & Innovation at Nottingham University Hospitals NHS Trust (NUH) has been presented with a special award for his significant contribution to commercial research in the NHS.
Dr Steve Ryder was one of five researchers in the UK recognised by the National Institute for Health Research (NIHR) for his outstanding contribution to commercial research over the past ten years.
Speaking after his award Dr Ryder, said: “Commercial research provides patients with access to many new drugs and treatments, which can achieve better clinical outcomes and potentially benefit all NHS patients in the future.
“Take liver disease for example. It is the fifth commonest cause of death in the UK and new treatments are needed. One cause of liver disease is a virus called hepatitis C, which causes scaring of the liver, known as Cirrhosis.
“Thanks to the commercial research undertaken here in Nottingham we have seen a revolution in new drugs to treat the disease. Many of the participants involved in clinical trials have been cured of their symptoms and new drugs are almost 100% effective at curing the infection and avoiding the long term ill effects of hepatitis C. This could not have been achieved without commercial research, supported by the NHS.
“It has been a real privilege to be involved in these life-changing studies.”
A further five researchers, based at NUH and The University of Nottingham were also recognised at the prestigious event in London that celebrated the expertise of commercial principal investigators. They were:
- Professor Philip Bath for consistently delivering to time and target
- Professor Stephen Chan for consistently delivering to time and target
- Dr Patrick Davies for recruiting the first global patient to a study at NUH
- Dr Christopher Gough for recruiting the first global patient to a study at NUH
- Professor Nikola Sprigg for developing innovative models of recruitment and commercial study delivery
Principal investigators are responsible for NIHR supported research sites, ensuring that patients are appropriately recruited into research studies.
Professor David Rowbotham, Clinical Director of the CRN: East Midlands, said: “It is fantastic to see a marked increase in the number of groundbreaking commercial studies being conducted across the East Midlands, by inspiring principal investigators like the ones at NUH, who are committed to offering more and more patients the opportunity to take part in life changing research.”
The NIHR is the research arm of the NHS and is funded through the Department of Health to improve the health and wealth of the nation through research.
Professor Chris Whitty, Chief Scientific Adviser at the Department of Health, said: “Principal Investigators continue to play a crucial role in the NIHR Clinical Research Network’s substantial progress in the growth and delivery of commercial contract research in the NHS.
“As we mark 10 years of the NIHR, I am delighted to celebrate these achievements which should inspire a new generation of research leaders.”